RDIF says no critical EMA remarks during Sputnik V’s registration in EU

The Russian Direct Investment Fund (RDIF) did not receive any critical remarks of the European Medicines Agency (EMA) during the procedure of Sputnik V vaccine’s registration in the European Union, the sovereign fund’s CEO Kirill Dmitriev told reporters.

"The timeframe of Sputnik V vaccine’s registration in the EU depends on the EMA. We have not received any critical remarks — neither clinical research nor critical remarks regarding the production. A working process is underway, which won’t be politicized as we hope," TASS cited Dmitriev as saying.

The RDIF submitted a request for registering Sputnik V in the EU in January, after completing scientific consultations with the EMA.